← Browse by Condition
Medical Condition
dlbcl diffuse large b cell lymphoma
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — dlbcl diffuse large b cell lymphoma Clinical Trials
How many clinical trials are currently recruiting for dlbcl diffuse large b cell lymphoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for dlbcl diffuse large b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for dlbcl diffuse large b cell lymphoma?
dlbcl diffuse large b cell lymphoma research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a dlbcl diffuse large b cell lymphoma clinical trial?
Eligibility criteria for dlbcl diffuse large b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06544265 Phase 1
Recruiting
Enrollment
36 pts
Location
United States
Sponsor
Verismo Therapeutics
NCT06481826
Recruiting
Enrollment
20 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT06026488
Recruiting
Enrollment
10,000 pts
Location
China
Sponsor
Ruijin Hospital
NCT07255963 Phase 2
Recruiting
Enrollment
29 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07249905 Phase 1, Phase 2
Recruiting
Enrollment
180 pts
Location
Australia
Sponsor
ModeX Therapeutics, An OPKO He...
NCT06158399 Phase 2
Recruiting
Enrollment
52 pts
Location
China
Sponsor
The First Affiliated Hospital ...
Related Conditions
lymphoma (2) b cell lymphoma (1) nhl adult (1) mantle cell lymphoma (1) relapsed non hodgkin lymphoma (1) refractory non hodgkin lymphoma (1) aggressive b cell non hodgkin lymphoma (1) indolent b cell non hodgkin lymphoma (1) follicular lymphoma (1) marginal zone lymphoma (1) hgbl with myc and bcl2 and or bcl6 rearrangements (1) high grade b cell lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology